이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III Trial

2026년 11월 14일 업데이트: Xuekui Liu

A Phase III, Open-Label, Multicenter, Randomized Clinical Trial of Neoadjuvant Camrelizumab Combined With Nab-Paclitaxel and Cisplatin in Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma

This is a Phase III, randomized, open-label, multicenter clinical study for patients with locally advanced, resectable head and neck squamous cell carcinoma (HNSCC).

The current standard treatment for this disease includes surgery or radiation, but many patients still experience tumor recurrence or metastasis. This study aims to evaluate whether adding an immunotherapy drug (Camrelizumab) to standard chemotherapy (nab-paclitaxel and cisplatin) before surgery or radiation can improve patient outcomes.

Participants will be randomly assigned in a 1:1 ratio to one of two groups:

Experimental Group: Receives 3 cycles of Camrelizumab combined with nab-paclitaxel and cisplatin as neoadjuvant (pre-operative) therapy.

Control Group: Receives 3 cycles of nab-paclitaxel and cisplatin as neoadjuvant therapy.

After 3 cycles of treatment, doctors will evaluate the tumors. Depending on the tumor response, its location, and the patient's preference, participants will then receive either surgery (radical resection) or radiation therapy combined with cisplatin.

The main goal of this study is to compare the 2-year Event-Free Survival (EFS) between the two groups to see if the addition of Camrelizumab can prevent the disease from progressing or coming back. We will also monitor overall survival, organ preservation rates, and safety.

연구 개요

상세 설명

Background:

Head and neck squamous cell carcinoma (HNSCC) is a common malignancy worldwide. For locally advanced resectable HNSCC, the standard treatment paradigm often involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. However, the 5-year survival rate remains suboptimal, and the optimal neoadjuvant regimen is still debated. Immunotherapy, particularly PD-1 inhibitors, has shown promising efficacy in recurrent/metastatic HNSCC. Our previous Phase II trial demonstrated that neoadjuvant Camrelizumab combined with nab-paclitaxel and cisplatin was safe and highly effective (Objective Response Rate of 89.6%). This Phase III study is designed to further validate these findings.

Study Design:

This is a randomized, open-label, multicenter, Phase III clinical trial. A total of 212 eligible patients with clinical stage III-IV (T2N2-3M0, T3-4N0-3M0, AJCC 8th) resectable HNSCC will be enrolled and randomized 1:1 to the experimental or control group.

Interventions:

Experimental Arm: Neoadjuvant Camrelizumab (200 mg, IV, Day 1) + nab-paclitaxel (260 mg/m², IV, Day 1) + cisplatin (60 mg/m², IV, Day 1) for 3 cycles (21-day cycle).

Control Arm: Neoadjuvant nab-paclitaxel (260 mg/m², IV, Day 1) + cisplatin (60 mg/m², IV, Day 1) for 3 cycles.

After 3 cycles, tumor response will be evaluated per RECIST v1.1. Patients with oropharyngeal, laryngeal, or hypopharyngeal cancer who achieve CR/PR and wish to preserve organ function will receive radical radiotherapy plus cisplatin; those with residual disease will undergo salvage surgery. Other patients will undergo radical surgery with organ preservation. Adjuvant therapy will be administered based on NCCN/CSCO guidelines and multidisciplinary team discussion.

Outcomes:

The primary endpoint is 2-year Event-Free Survival (EFS). Secondary endpoints include 2-year Overall Survival (OS), 2-year Progression-Free Survival (PFS), organ preservation rate, Disease Control Rate (DCR), Objective Response Rate (ORR), safety, quality of life (EORTC QLQ-C30 and QLQ-H&N35), and exploratory biomarker analysis (PD-L1 CPS, TMB, etc.).

연구 유형

중재적

등록 (추정된)

212

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • 1. Histologically and/or cytologically confirmed, previously untreated head and neck squamous cell carcinoma (diagnostic treatment excluded).

    2. Clinical stage T2N2-3M0 or T3-4N0-3M0 (Stage III-IV, AJCC 8th edition). 3. Age between 18 and 70 years. 4. ECOG Performance Status (PS) of 0 or 1. 5. Assessed by a head and neck oncologist as resectable with no distant metastasis.

    6. At least one evaluable lesion according to RECIST v1.1. 7. Adequate organ function to tolerate surgery:

  • Hematology: WBC ≥ 4000/μL, ANC ≥ 2.000/μL, Hemoglobin ≥ 9 g/dL, Platelets ≥ 100,000/μL.

  • Liver function: Bilirubin ≤ 1.5× ULN, AST/ALT ≤ 3× ULN, ALP ≤ 3× ULN, Albumin ≥ 3 g/dL.

  • Renal function: Serum creatinine ≤ 1.5× ULN or Cockcroft-Gault creatinine clearance ≥ 60 mL/min.

    8. Signed informed consent and willingness to comply with study procedures.

Exclusion Criteria:

  • 1. History of severe hypersensitivity to other monoclonal antibodies or any component of PD-1 monoclonal antibodies.

    2. Known or suspected autoimmune diseases, including dementia and epilepsy. 3. Recurrent disease, distant metastasis, concurrent other malignancies, or assessed as unresectable.

    4. Coagulation abnormalities (PT > 16s, APTT > 53s, TT > 21s, Fib < 1.5g/L), bleeding tendency, or receiving thrombolytic/anticoagulant therapy.

    5. Severe heart or lung disease; cardiac or pulmonary function below grade 3 (including grade 3).

    6. Laboratory test values within 7 days prior to enrollment not meeting the relevant standards.

    7. Prior use of anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies (or any other antibody targeting T-cell co-stimulation or checkpoint pathways).

    8. Comorbidities requiring long-term immunosuppressive therapy or systemic/local use of immunosuppressive doses of corticosteroids prior to enrollment.

    9. HIV positive; HBsAg positive with detectable HBV DNA (≥ 1000 cps/ml); positive blood screening for chronic hepatitis C (HCV antibody positive).

    10. Use of anti-tumor traditional Chinese herbal medicine within 4 weeks prior to randomization.

    11. Pregnant or lactating women.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Camrelizumab plus Chemotherapy

Patients receive neoadjuvant Camrelizumab (200 mg, IV, Day 1) combined with nab-paclitaxel (260 mg/m², IV, Day 1) and cisplatin (60 mg/m², IV, Day 1) every 3 weeks for 3 cycles, followed by surgery or radiotherapy based on tumor response.

Humanized anti-PD-1 monoclonal antibody administered intravenously at 200 mg on Day 1 of each 21-day cycle for 3 cycles.

다른 이름들:
  • SHR-1210

Administered intravenously at 260 mg/m² on Day 1 of each 21-day cycle for 3 cycles.

다른 이름들:
  • 알부민 결합 파클리탁셀

Administered intravenously at 60 mg/m² on Day 1 of each 21-day cycle for 3 cycles.

다른 이름들:
  • CDDP
활성 비교기: Chemotherapy Alone

Patients receive neoadjuvant nab-paclitaxel (260 mg/m², IV, Day 1) and cisplatin (60 mg/m², IV, Day 1) every 3 weeks for 3 cycles, followed by surgery or radiotherapy based on tumor response.

Administered intravenously at 260 mg/m² on Day 1 of each 21-day cycle for 3 cycles.

다른 이름들:
  • 알부민 결합 파클리탁셀

Administered intravenously at 60 mg/m² on Day 1 of each 21-day cycle for 3 cycles.

다른 이름들:
  • CDDP

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
2-year Event-Free Survival (EFS) Rate
기간: 2 years from randomization

Event-Free Survival (EFS) is defined as the time from randomization to the first occurrence of any of the following events: disease progression that precludes surgery, local or distant recurrence, treatment termination due to toxicity or complications, or death from any cause. The rate at 2 years will be calculated.

2 years from randomization

2차 결과 측정

결과 측정
측정값 설명
기간
2-year Overall Survival (OS) Rate
기간: 2 years from randomization

The percentage of patients alive at 2 years from randomization. If the patient died within 2 years, it will be censored at the last known alive date.

2 years from randomization

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 1월 1일

기본 완료 (추정된)

2029년 1월 1일

연구 완료 (추정된)

2030년 1월 1일

연구 등록 날짜

최초 제출

2026년 11월 14일

QC 기준을 충족하는 최초 제출

2026년 11월 14일

처음 게시됨 (실제)

2026년 11월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 14일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다